Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 1
1957 1
1961 1
1964 1
1966 2
1968 2
1970 2
1971 4
1972 3
1974 1
1975 1
1978 1
1979 3
1980 2
1981 7
1982 9
1983 7
1984 6
1985 4
1986 8
1987 8
1988 8
1989 8
1990 15
1991 18
1992 7
1993 12
1994 14
1995 17
1996 21
1997 15
1998 35
1999 28
2000 25
2001 24
2002 25
2003 22
2004 37
2005 36
2006 36
2007 53
2008 45
2009 52
2010 47
2011 58
2012 51
2013 41
2014 57
2015 45
2016 57
2017 67
2018 66
2019 63
2020 65
2021 62
2022 51
2023 38
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

1,258 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. Among authors: yokoi t. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Free article. Clinical Trial.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: yokoi t. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Identification of a unique subset of tissue-resident memory CD4+ T cells in Crohn's disease.
Yokoi T, Murakami M, Kihara T, Seno S, Arase M, Wing JB, Søndergaard JN, Kuwahara R, Minagawa T, Oguro-Igashira E, Motooka D, Okuzaki D, Mori R, Ikeda A, Sekido Y, Amano T, Iijima H, Ozono K, Mizushima T, Hirota S, Ikeuchi H, Takeda K. Yokoi T, et al. Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2204269120. doi: 10.1073/pnas.2204269120. Epub 2022 Dec 27. Proc Natl Acad Sci U S A. 2023. PMID: 36574662 Free PMC article.
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: yokoi t. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.
Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H. Fujimoto D, et al. Among authors: yokoi t. JAMA Netw Open. 2023 Feb 1;6(2):e230698. doi: 10.1001/jamanetworkopen.2023.0698. JAMA Netw Open. 2023. PMID: 36826813 Free PMC article.
Diagnosis and Treatment of Myopic Maculopathy.
Yokoi T, Ohno-Matsui K. Yokoi T, et al. Asia Pac J Ophthalmol (Phila). 2018 Nov-Dec;7(6):415-421. doi: 10.22608/APO.2018290. Epub 2018 Sep 26. Asia Pac J Ophthalmol (Phila). 2018. PMID: 30255668 Free article. Review.
Current and emerging pharmaceutical interventions for myopia.
Vutipongsatorn K, Yokoi T, Ohno-Matsui K. Vutipongsatorn K, et al. Among authors: yokoi t. Br J Ophthalmol. 2019 Nov;103(11):1539-1548. doi: 10.1136/bjophthalmol-2018-313798. Epub 2019 May 16. Br J Ophthalmol. 2019. PMID: 31097440 Review.
Imaging of Pathologic Myopia.
Ohno-Matsui K, Fang Y, Shinohara K, Takahashi H, Uramoto K, Yokoi T. Ohno-Matsui K, et al. Among authors: yokoi t. Asia Pac J Ophthalmol (Phila). 2019 MarchApril 01;8(2):172-177. doi: 10.22608/APO.2018494. Asia Pac J Ophthalmol (Phila). 2019. PMID: 30924327 Free article.
1,258 results